Abstract |
Thirty-eight of forty patients satisfactorily concluded a double-blind, placebo-controlled trial to study the effects of pirenzepine (100 mg/day) on duodenal ulcers. After six weeks of treatment 14 of 18 patients (78%) in the pirenzepine-treated group and 7 of 20 patients (35%) in the placebo groups were healed. There was a statistically significant difference (P less than 0.05). The relief of day-time and night-time pain was significantly greater in the pirenzepine-treated group. Pirenzepine-treated patients consumed significantly fewer antacid tablets. The tolerability of pirenzepine was good. Pirenzepine (100 mg/day for six weeks) should be an effective and safe treatment for duodenal ulcers.
|
Authors | D Do, S Martelli, S Daniotti |
Journal | Scandinavian journal of gastroenterology. Supplement
(Scand J Gastroenterol Suppl)
Vol. 72
Pg. 211-4
( 1982)
ISSN: 0085-5928 [Print] England |
PMID | 6753115
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antacids
- Anti-Ulcer Agents
- Benzodiazepinones
- Pirenzepine
|
Topics |
- Adult
- Antacids
(therapeutic use)
- Anti-Ulcer Agents
(therapeutic use)
- Benzodiazepinones
(therapeutic use)
- Clinical Trials as Topic
- Double-Blind Method
- Duodenal Ulcer
(drug therapy)
- Female
- Humans
- Male
- Pain
(drug therapy)
- Pirenzepine
- Time Factors
|